{
    "nct_id": "NCT05780905",
    "official_title": "Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes",
    "inclusion_criteria": "1. Men and women 40-65 years of age\n2. Subjects with type-2 diabetes >= 3 years and HbA1C 7%-10% with blood sugar control medications including insulin, metformin, sulfonylureas, or SGLT2 inhibitors\n3. Medically stable\n4. Has not received any investigational drug in the past 6 months\n5. Willing to participate and sign informed consent.\nHealthy volunteers allowed\nMust have minimum age of 40 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "1. Contraindication to MRI or contrast agent\n2. eGFR<45 mL/min/1.73m2 (eGFR is a measurement of kidney function)\n3. Currently treated with glucagon-like peptide-1 receptor antagonist (same drug class as study intervention)\n4. Unable to perform home-glucose monitoring\n5. Currently need more than 100 units of insulin daily\n6. Uncontrolled hypertension with systolic blood pressure (SBP)>180 mmHg or diastolic blood pressure (DBP)>100 mmHg\n7. LDL-C>130 mg/dL or not on stable statin therapy in the past 6 months\n8. Treatment with pioglitazone in the past 3 months\n9. History of pancreatitis\n10. History of myocardial infarction, stroke or transient ischemic attack\n11. History or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n12. Hypersensitivity to semaglutide or any of the product components\n13. Participating in other clinical trial\n14. Women of child-bearing potential (ie, those who are not chemically or surgically sterilized or who are not post-menopausal) who have a positive pregnancy test at enrollment or who are breastfeeding or who plan to become pregnant in the next 15 months.",
    "miscellaneous_criteria": ""
}